Tavo-101 is under clinical development by Tavotek Biotherapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tavo-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tavo-101 overview
Tavo-101 is under development for the treatment of various kinds of allergies and atopic dermatitis. It is administered through intravenous route. It is a human monoclonal TSLP antibody. The drug candidate is being developed based on TavoPrecise antibody platform.
Tavotek Biotherapeutics overview
Tavotek Biotherapeutics (Tavotek) is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for oncology, autoimmune and inflammatory diseases. The company’s proprietary TavoMIP Platform uses small molecule and antibody drugs for Binding and targeting intracellular tumors; TavoSelect provides human antibody sequences that can be utilized in different formats using computational analysis and machine learning; and TavoPrecise, a fit-for-purpose monoclonal antibody, and multi-specific to identify unique epitopes. It has an operational presence in China. The company works in collaboration with Yisheng Biopharma Co Ltd, to discover, develop and commercialize biotherapeutics for cancer and infectious disease using its novel PIKA immunomodulating technology. Tavotek is headquartered in Lower Gwynedd, Pennsylvania, the US.
For a complete picture of Tavo-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
